ArticleEClinicalMedicine2025

Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands.

Hanneke van Laarhoven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.